Halozyme completes call of second tranche of warrants

By Elaine Rigoli

Tampa, Fla., Sept. 13 - Halozyme Therapeutics, Inc. announced that warrant holders exercised warrants to purchase 2,204,188 shares of its common stock for total cash proceeds of $3.9 million.

These warrant exercises occurred over the past few weeks in connection with Halozyme's previously announced warrant call. Based on the number of shares subject to this warrant call, the company said it originally anticipated receiving gross proceeds of $3.3 million, if all shares subject to the warrant call were exercised.

A number of the company's warrant holders decided to exercise their warrants for an amount of shares greater than what was required by the warrant call, leading to the company's receipt of $0.6 million in additional gross proceeds.

Halozyme said it intends to redeem 26,900 warrants that were not exercised in connection with the call for $0.01 per share, or $283.

Halozyme is a biopharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.